A C. diff infection can come back even after antibiotic treatment.

RETURN TO YOU

Prevent recurrence of C. diff infection with REBYOTA^™

What Is REBYOTA?

After being treated for a C. diff infection, did it come back?

REBYOTA is the first and only FDA approved microbiome-based treatment to prevent recurrent C. diff infection, after you’ve already taken antibiotics¹

Learn about the microbiome and recurrent C. diff infection

This is Melissa’s Story

Had this treatment been available sooner, I would have asked for it….The healing process began after I had it.

Watch Melissa’s Story

Most common side effects may include stomach pain, diarrhea, bloating, gas, and nausea.

For more information, please talk to your doctor and see full Prescribing Information. Melissa was compensated for her time. Individual results may vary.

Image of Melissa, clinical study patient — Melissa, Clinical Study Patient

When a C. diff infection comes back, it’s called recurrent C. diff.

C. diff can be a gut-wrenching experience. Even after antibiotic treatment, for some people, it can come back more than once:

Up to 35% of people who get a C. diff infection may have a recurrence^6,7

Up to 65% of people who experience a recurrence may have a second or third or more^8,9

REBYOTA offers hope for people with recurrent C. diff.

Treatment With REBYOTA

FDA approved microbiome-based treatment to prevent the recurrence of C. diff.

Treatment With REBYOTA

REBYOTA Support & Resources

Explore savings options including how you could PAY NO MORE THAN $100.^a

Savings and Support

^aTerms and conditions apply.

If you’re ready to talk to a doctor, this customized discussion guide is a great way to prepare.

Build Your Guide

Sign up for more information

Receive additional information and resources to help you through your C. diff infection journey.

First Name*(Required)

Last Name*(Required)

Email Address*(Required)

Phone Number

What’s your experience with C. diff infection?*(Required)

What’s your experience with C. diff infection?*

I currently have a C. diff infection

I had a C. diff infection within the last year

I am a C. diff patient caregiver

I’m interested in learning more about C. diff

*Required field.

Consent(Required)

I CONSENT(Required)

By providing the information requested, I am giving Ferring permission to store and use the information that I have provided. I understand and agree that my information will be used by Ferring (or companies working on Ferring’s behalf) to contact me by telephone, email, or mail to provide me with information that may be of interest to me or to invite me to participate in research, educational, and marketing initiatives. I understand that my information will be treated as described in Ferring’s Privacy Notice, which provides details about my privacy rights. Also, I understand that I may opt out of the database at any time by making the request at Data Subject Form or by calling 1-888-FERRING, Monday through Friday, 8 _AM to 7 _PM ET to speak to a representative or leave a voicemail. This statement may be updated from time to time.

References

REBYOTA. Prescribing Information. Parsippany, NJ: Ferring Pharmaceuticals Inc; 2022.
Lessa FC, Mu Y, Bamberg WM, et al. Burden of Clostridium difficile infection in the United States.  N Engl J Med. 2015;372(9):825-834.
Cornely OA, Miller MA, Louie TJ, Crook DW, Gorbach SL. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin. Clin Infect Dis. 2012;55(suppl 2):S154-S161.
Kelly CP. Can we identify patients at high risk of recurrent Clostridium difficile infection? Clin Microbiol Infect. 2012;18(suppl 6):21-27.
Smits WK, Lyras D, Lacy DB, Wilcox MH, Kuijper EJ. Clostridium difficile infection. Nat Rev Dis Primers. 2016;2:16020.

Please see Important Safety Information and full Prescribing Information

INDICATION

REBYOTA (fecal microbiota, live – jslm) is indicated for the prevention of recurrence of Clostridioides difficile (C. diff) infection in individuals
18 years of age and older, following antibiotic treatment for recurrent C. diff infection.
Limitation of Use
REBYOTA is not indicated for the treatment of C. diff infection.

Important Safety Information

You should not receive REBYOTA if you have a history of a severe allergic reaction (e.g., anaphylaxis) to REBYOTA or any of its components.
You should report to your doctor any infection you think you may have acquired after administration.
REBYOTA may contain food allergens.
Most common side effects may include stomach pain (8.9%), diarrhea (7.2%), bloating (3.9%), gas (3.3%), and nausea (3.3%).
REBYOTA has not been studied in patients below 18 years of age.
Clinical studies did not determine if adults 65 years of age and older responded differently than younger adults.

You are encouraged to report negative side effects of prescription drugs to FDA. Visit www.FDA.gov/medwatch or call 1-800-332-1088.

Please click to see the full Prescribing Information

RETURN TO YOU

Prevent recurrence of C. diff infection with REBYOTA™

REBYOTA is the first and only FDA approved microbiome-based treatment to prevent recurrent C. diff infection, after you’ve already taken antibiotics1

When a C. diff infection comes back, it’s called recurrent C. diff.

Up to 35% of people who get a C. diff infection may have a recurrence6,7

Up to 65% of people who experience a recurrence may have a second or third or more8,9

REBYOTA offers hope for people with recurrent C. diff.

Treatment With REBYOTA

REBYOTA Support & Resources

If you’re ready to talk to a doctor, this customized discussion guide is a great way to prepare.

Sign up for more information

References

Please see Important Safety Information and full Prescribing Information

INDICATION

Important Safety Information

You are leaving REBYOTA.com

Prevent recurrence of C. diff infection with REBYOTA^™

REBYOTA is the first and only FDA approved microbiome-based treatment to prevent recurrent C. diff infection, after you’ve already taken antibiotics¹

Up to 35% of people who get a C. diff infection may have a recurrence^6,7

Up to 65% of people who experience a recurrence may have a second or third or more^8,9